Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  ALPN
Alpine Immune Sciences Inc
ALPN
72 / 100
$64.50arrow_drop_up0.15%$0.10

Performance History

Stocklytics logo
Key Stats
Open$64.40
Prev. Close$64.40
EPS-0.64
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.08B
PE Ratio-
LOWHIGH
Day Range64.37
64.57
52 Week Range6.71
64.57
Ratios
P/B Ratio12.86
Revenue$58.87M
Operating M. %5.01%
Earnings$0.00
Earnings Growth %44.28%
EBITDA Margin %-74.18%
ROE %-12.69%
EPS-0.64

Score Breakdown

72vs 55. Market Avg.

All Score 72 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ALPNMARKET
Value3040
Quality6740
Ownership4017
Growth6945
Dividends-37
check_circle

Alpine Immune Sciences Inc's Price growth average in the last 3 years of 252.17% is great compared to market average of 7.16%. This indicates ALPN could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$752.47
24H (%)arrow_drop_down0.93%
24H ($)-$7.12
MARKET CAP$724.46B
PRICE$438.63
24H (%)arrow_drop_down0.69%
24H ($)-$3.09
MARKET CAP$414.91B
PRICE$147.37
24H (%)arrow_drop_down0.95%
24H ($)-$1.41
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Alpine Immune Sciences Inc (ALPN)

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mitchell H. Gold M.D.
Headquarters
Seattle
Employees
126
Exchange
NASDAQ
add Alpine Immune Sciences Inc to watchlist

Keep an eye on Alpine Immune Sciences Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Alpine Immune Sciences Inc's (ALPN) price per share?

The current price per share for Alpine Immune Sciences Inc (ALPN) is $64.5. The stock has seen a price change of $0.1 recently, indicating a 0.16% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Alpine Immune Sciences Inc (ALPN)?

For Alpine Immune Sciences Inc (ALPN), the 52-week high is $64.57, which is 0.11% from the current price. The 52-week low is $6.71, the current price is 861.25% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Alpine Immune Sciences Inc (ALPN) a growth stock?

Alpine Immune Sciences Inc (ALPN) has shown an average price growth of 252.17% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Alpine Immune Sciences Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Alpine Immune Sciences Inc (ALPN) stock price performance year to date (YTD)?

As of the latest data, Alpine Immune Sciences Inc (ALPN) has a year-to-date price change of 239.47%. Over the past month, the stock has experienced a price change of 76.95%. Over the last three months, the change has been 215.4%. Over the past six months, the figure is 490.12%. Looking at a longer horizon, the five-year price change stands at 765.77%.

help
Is Alpine Immune Sciences Inc (ALPN) a profitable company?

Alpine Immune Sciences Inc (ALPN) has a net income of -$32.18M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 5.01% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $58.88M, with a revenue growth rate of 95.84%, providing insight into the company's sales performance and growth. The gross profit is $58.3M. Operating income is noted at -$44.25M. Furthermore, the EBITDA is -$43.67M.

help
What is the market capitalization of Alpine Immune Sciences Inc (ALPN)?

Alpine Immune Sciences Inc (ALPN) has a market capitalization of $3.08B. The average daily trading volume is 5.77M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.